Ticker

Aditxt, Inc. (NASDAQ: ADTX - Get Free Report) saw a large decrease in short interest in January. As of January 30th, there was short interest totaling 49,980 shares, a decrease of 53.4% from the January 15th total of 107,279 shares. Currently, 6.8% of the company's stock are sold short. Based on an average trading volume of

Aditxt (NASDAQ: ADTX - Get Free Report) and Avalo Therapeutics (NASDAQ: AVTX - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability. Profitability This table compares Aditxt and Avalo Therapeutics'

Aditxt, Inc. (NASDAQ: ADTX - Get Free Report) was the target of a large decline in short interest in the month of December. As of December 15th, there was short interest totaling 86,655 shares, a decline of 31.2% from the November 30th total of 125,952 shares. Approximately 11.9% of the company's shares are short sold. Based

U.S. stock futures rose on Wednesday after Tuesday's mixed close. Futures of major benchmark indices advanced.

Aditxt shares surged 52% after hours following the company's filing of a definitive proxy statement for a special stockholder meeting in January 2026.